Is PLX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for PLX. It does not provide personalized investment advice.

PLX (Protalix BioTherapeutics, Inc. Common Stock) Stock Analysis - Financials

Protalix BioTherapeutics, Inc. Common Stock (PLX) is a publicly traded Healthcare sector company. As of October 26, 2026, PLX trades at $2.55 with a market cap of $205.46M and a P/E ratio of 11.56. PLX moved +0.00% today. Year to date, PLX is +41.67%; over the trailing twelve months it is +10.39%. Its 52-week range spans $1.32 to $3.19. Analyst consensus is buy with an average price target of $12.00. Rallies surfaces PLX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are PLX's key financials?

PLX financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. PLX recently traded at $2.55. Market cap is $205.46M. P/E ratio is 11.56. Revenue is $80.62M.

PLX Key Metrics

Key financial metrics for PLX
Metric	Value
Price	$2.55
Market Cap	$205.46M
P/E Ratio	11.56
EPS	$0.24
Dividend Yield	0.00%
52-Week High	$3.19
52-Week Low	$1.32
Volume	278
Avg Volume	0
Revenue (TTM)	$80.62M
Net Income	$18.95M
Gross Margin	69.20%

PLX Analyst Consensus

1 analysts cover PLX: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $12.00.

Common questions about PLX

What are PLX's key financials?: PLX financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. PLX recently traded at $2.55. Market cap is $205.46M. P/E ratio is 11.56. Revenue is $80.62M.
Is PLX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for PLX. It does not provide personalized investment advice.